Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

London

CAR-TCR Summit Europe 2025

This summit will focus on the next-generation innovations in cell therapy. Attendees can expect discussions on the latest breakthroughs, particularly in treating solid tumours and [...]

Go to Top